INSTANT-2NCT07842185
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
At risk: Enrollment reduced 20%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date pushed from Nov 19, 2026 to Dec 19, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 66 words
- Enrollment reduced: 1482 → 1192 participants
- Interventions modified
- Trial arms changed: 3 → 2
- Study title shortened, about 2 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of patients with mRS 0-1 at 90 days
Timeframe: 90 days after randomization
Secondary (5)
mRS score at 90 days
EQ-5D-5L score at 90 days
Proportion of patients with mRS 0-2 at 90 days
Proportion of patients with mRS 0-3 at 90 days
Proportion of early neurological improvement
Arms and interventions
Arm A: Tirofiban 24-hour groupExperimental
Arm A: Patients receive tirofiban for 24 hours after intravenous thrombolysis.
Arm B: Tirofiban 48-hour groupExperimental
Arm B: Patients receive tirofiban for 48 hours after intravenous thrombolysis.
Drugs: Tirofiban Injection
Sites
10 sites in 1 country